Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio

Repligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio

Includes Preclinical Compounds for Potential Treatment of Friedreich's Ataxia

WALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Repligen Corporation
(Nasdaq:RGEN) announced today that it has entered into an asset purchase
agreement with BioMarin Pharmaceutical Inc. ("BioMarin") to advance Repligen's
histone deacetylase inhibitor (HDACi) portfolio. The HDACi portfolio includes
multiple orally bioavailable small molecule compounds as well as enabling
technologies. Under the terms of the agreement, Repligen will receive an
upfront payment of $2 million from BioMarin and it has the potential to
receive up to $160 million in future milestone payments for the development,
regulatory approval and commercial sale of portfolio compounds included in the
agreement. In addition, Repligen is eligible to receive royalties on sales of
therapeutic products originating from the HDACi portfolio. Potential
applications of the HDACi portfolio include Friedreich's ataxia and other
neurological disorders.

"The outlicensing of our HDAC portfolio, which includes the Friedreich's
ataxia program, is consistent with our objective to realize financial value
from discontinued therapeutic development programs as we fully focus on the
expansion of Repligen's bioprocessing business," said Walter C. Herlihy,
Ph.D., President and Chief Executive Officer of Repligen. "BioMarin is an
ideal partner for the HDACi program based on the company's history of
successfully developing and commercializing first-to-market and best-in-class
therapies for people with serious rare disorders."

About Friedreich's ataxia

Friedreich's ataxia (FA) is a progressive, neurological disorder that affects
approximately 20,000 people in the United States and Europe, typically
resulting in wheelchair dependence in young adulthood and early death due to
cardiac failure. It is caused by mutations in the FXN gene, and is inherited
in an autosomal recessive manner. FXN mutations result in reduced expression
of frataxin protein, manifesting in progressive neurological and cardiac
damage. Major neurological symptoms include muscle weakness and ataxia, a loss
of balance and coordination. These symptoms typically appear between 10 and 15
years of age, but FA has been diagnosed in people from ages 2 to 50 with
earlier onset associated with a more severe course.

About Repligen Corporation

Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the
development, production and commercialization of high-value consumable
products used in the process of manufacturing biological drugs. Our
bioprocessing products are sold to major life sciences and biopharmaceutical
companies worldwide. We are a leading manufacturer of Protein A, a critical
reagent used to separate and purify monoclonal antibody therapeutics. We also
supply several growth factor products used to increase cell culture
productivity during the fermentation stage of drug manufacturing. In addition,
we have developed and market our OPUS^® line of pre-packed "plug-and-play"
chromatography columns, and we provide test kits to ensure final product
quality. Repligen's corporate headquarters are in Waltham, MA (USA) and our
manufacturing facilities are located in Waltham, MA and Lund, Sweden.

This press release may contain forward-looking statements, which are made
pursuant to the safe harbor provisions of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Investors are cautioned that statements in this press release which
are not strictly historical statements including, without limitation, express
or implied statements regarding the potential utility of compounds and
technologies in the HDACi portfolio for the treatment of Friedreich's ataxia
and other neurological disorders; the clinical success of compounds and
technologies in the HDACi portfolio and any further clinical development and
our receipt of any future payments under the terms of our agreement with
BioMarin; our strategic decision to focus on the growth of our bioprocessing
business, the future demand for our bioprocessing, growth factor and
chromatography products; plans and objectives for future operations; our
ability to successfully negotiate and consummate partnering transactions for
our clinical stage assets; plans and objectives for product development and
acquisitions; plans and objectives for regulatory approval, product
development, our market share and product sales and other statements
identified by words like "believe," "expect," "may," "will," "should," "seek,"
or "could" and similar expressions, constitute forward-looking statements.
Such forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
anticipated, including without limitation, risks associated with: the success
of clinical trials; our ability to successfully grow our bioprocessing
business, including as a result of acquisition, commercialization or
partnership opportunities; our ability to successfully negotiate and
consummate development and commercialization partnerships for our portfolio of
clinical-stage assets on acceptable terms, if at all; our ability to develop
and commercialize products and the market acceptance of our products; reduced
demand for our products that adversely impacts our future revenues, cash
flows, results of operations and financial condition; the ability to obtain,
and the timing and receipt of, FDA or other regulatory approval; the success
of current and future collaborative or supply relationships; our ability to
compete with larger, better financed bioprocessing, pharmaceutical and
biotechnology companies; new approaches to the treatment of our targeted
diseases; our compliance with all Food and Drug Administration and EMEA
regulations; our ability to obtain, maintain and protect intellectual property
rights for our products; the risk of litigation regarding our intellectual
property rights; our limited sales capabilities; our volatile stock price; and
other risks detailed in Repligen's Annual Report on Form 10-K on file with the
Securities and Exchange Commission and other reports that Repligen
periodically files with the Securities and Exchange Commission. Actual results
may differ materially from those Repligen contemplated by these forward
looking statements. These forward looking statements reflect management's
current views and Repligen does not undertake to update any of these
forward-looking statements to reflect a change in its views or events or
circumstances that occur after the date hereof except as required by law.

CONTACT: Repligen Corporation
         Sondra Newman
         Director Investor Relations
         (781) 419-1881
         snewman@repligen.com
 
Press spacebar to pause and continue. Press esc to stop.